Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for intravenous infusion. Bevacizumab is used in the treatment of various cancers, including metastatic colorectal cancer, recurrent or metastatic non-squamous non-small cell lung cancer, advanced and/or metastatic renal cell carcinoma, cervical cancer, epithelial ovarian, fallopian tube, and primary peritoneal cancer. Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The pharma major reported a 7.95% rise in consolidated net profit to Rs 817.38 crore on a 6.93% increase in revenue from operations to Rs 7,646.21 crore in Q2 FY25 over Q2 FY24. Shares of Aurobindo Pharma fell 1.17% to close at Rs 1,240.70 on Friday, 20 December 2024.Powered by Capital Market - Live

The United States Food and Drug Administration (US FDA) inspected Unit-V, an API manufacturing facility, of Apitoria Pharma, a wholly owned subsidiary of Auro Pharma, situated at Pashamylaram Village, Patancheru Mandal, Sanga Reddy District, Telangana from 9 December to 17 December 2024. The inspection closed with 2 observations. The observations are of procedural in nature and will be responded to within the stipulated time, stated the drug maker. Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The pharma major reported 7.95% rise in consolidated net profit to Rs 817.38 crore on a 6.93% increase in revenue from operations to Rs 7,646.21 crore in Q2 FY25 over Q2 FY24. Shares of Aurobindo Pharma gained 3.01% to Rs 1,250 on the BSE.Powered by Capital Market - Live

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-V, an API manufacturing facility, of Apitoria Pharma, a wholly owned subsidiary of the Company, situated at Pashamylaram Village, Patancheru Mandal, Sanga Reddy District, Telangana from 09 December to 17 December 2024. The inspection closed with 02 observations. The observations are of procedural in nature and will be responded to within the stipulated time. Powered by Capital Market - Live

The CHMP has recommended the granting of marketing authorization for Zefylti, which is intended for the treatment of neutropenia and the mobilization of peripheral blood progenitor cells (PBPCs). The company's spokesperson said, After receiving the GMP certificate of compliance from the European Medicines Agency (EMA) in November, Zefylti is our first biosimilar to receive a positive opinion from EMA's CHMP. Two more products, our biosimilar versions of pegylated filgrastim (BP14) and trastuzumab (BP02), are currently under review with the EMA, and a biosimilar to bevacizumab (BP01) is under review with the MHRA. We are confident and on track to bring these treatment options to patients next year. Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The pharma major reported 7.95% rise in consolidated net profit to Rs 817.38 crore on a 6.93% increase in revenue from operations to Rs 7,646.21 crore in Q2 FY25 over Q2 FY24. Shares of Aurobindo Pharma shed 0.59% to settle at Rs 1,207.95 on 13 December 2024. Powered by Capital Market - Live

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma,  announced that the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) has adopted a positive opinion for Zefylti (BP13, a filgrastim biosimilar) recommending the granting of a marketing authorisation. Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells (PBPCs). Commenting on the update the company spokesperson said, After receiving the GMP certificate of compliance from the European Medicines Agency (EMA) in November, Zefylti is our first biosimilar to receive a positive opinion from EMA's CHMP. Two more products, our biosimilar versions of pegylated filgrastim (BP14) and trastuzumab (BP02), are currently under review with the EMA, and a biosimilar to bevacizumab (BP01) is under review with the MHRA. We are confident and on track to bring these treatment options to patients next year.Powered by Capital Market - Live

Aurobindo Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 1198, down 1.37% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.24% on the day, quoting at 24608.35. The Sensex is at 81455.03, up 0.2%.Aurobindo Pharma Ltd has eased around 4.08% in last one month.Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has increased around 1.53% in last one month and is currently quoting at 22229.3, down 0.65% on the day. The volume in the stock stood at 7.22 lakh shares today, compared to the daily average of 10 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 1201.9, down 1.46% on the day. Aurobindo Pharma Ltd jumped 14.6% in last one year as compared to a 16.17% rally in NIFTY and a 36.71% spurt in the Nifty Pharma index.The PE of the stock is 34.41 based on TTM earnings ending September 24.Powered by Capital Market - Live

The approved drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Votrient Tablets, of Novartis Pharmaceuticals Corporation. Pazopanib Tablets, is indicated for the treatment of adults with advanced renal cell carcinoma (RCC), and advanced soft tissue sarcoma (STS) who have received prior chemotherapy. The product is expected to be launched in Q4 FY25. The approved product has an estimated market size of $106 million for the twelve months ending October 2024, according to IQVIA. This is the 179 th ANDA approval (including 8 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oncology oral and sterile specialty products. Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The pharma major reported 7.95% rise in consolidated net profit to Rs 817.38 crore on a 6.93% increase in revenue from operations to Rs 7,646.21 crore in Q2 FY25 over Q2 FY24. Shares of Aurobindo Pharma declined 0.98% to Rs 1,245.70 on the BSE. Powered by Capital Market - Live

Aurobindo Pharma announced that its wholly owned subsidiary company, Eugia Pharma Specialities, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Pazopanib Tablets, 200 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Votrient Tablets, 200 mg, of Novartis Pharmaceuticals Corporation. The product is expected to be launched in Q4FY25. The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA. This is the 179 th ANDA approval (including 8 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oncology oral and sterile specialty products. Pazopanib Tablets, 200 mg is indicated for the treatment of adults with Advanced Renal Cell Carcinoma (RCC), and Advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy.Powered by Capital Market - Live

The headline equity benchmarks continued to trade with major gains in morning trade after the outcomes of the Maharashtra and Jharkhand elections. Additionally, macroeconomic indicators, including GDP and infrastructure output, will garner significant attention. The Nifty hovered above the 24,300 level. PSU bank shares extended gains for the second consecutive trading session. At 10:30 ST, the barometer index, the S&P BSE Sensex, soared 1,256.78 points or 1.59% to 80,394.32. The Nifty 50 index surged 408.10 points or 1.71% to 24,315.35. The broader market outperformed the benchmark indices. The S&P BSE Mid-Cap index added 1.89% and the S&P BSE Small-Cap index gained 1.88%. The market breadth was strong. On the BSE, 2,888 shares rose and 805 shares fell. A total of 200 shares were unchanged. Economy: India's foreign exchange reserves declined $17.761 billion, reaching $657.892 billion for the week ended November 15, as reported by the RBI on Friday. In the prior week ending November 8, the forex declined $6.477 billion to $675.653 billion. The central bank also reported that gold reserves reduced by $2.068 billion to $65.746 billion during this period. It also indicated that Special Drawing Rights (SDRs) decreased by $94 million to $18.064 billion. Additionally, India's reserve position with the IMF also declined by $51 million, reaching $4.247 billion in the reporting week. Buzzing Index: The Nifty PSU Bank index gained 4.62% to 6,808.75. The index advanced 7.75% in two consecutive trading sessions. Indian Bank (up 8.82%), UCO Bank (up 7.67%), Central Bank of India (up 5.33%), Punjab & Sind Bank (up 5.24%) and Punjab National Bank (up 4.91%), Indian Overseas Bank (up 4.81%), Bank of Baroda (up 4.43%), Union Bank of India (up 4.26%), Canara Bank (up 3.79%) and Bank of Maharashtra (up 3.76%). edged higher. Stocks in Spotlight: Aurobindo Pharma added 1.41% after the company's wholly owned subsidiary, Aurobindo Pharma USA Inc entered into a collaboration and license agreement with a global pharma major. Bliss GVS Pharma gained 2.24% after the company's Maharashtra-based facilities received a GMP compliance certificate from the National Agency for Medicines and Medical Devices of Romania post an EU GMP inspection. Powered by Capital Market - Live

The agreement is for development of specific products across respiratory therapeutic area and their commercialisation. The agreement is for an initial estimated development duration of three- five years. Both the parties will collaborate with respect to the development of specific products across respiratory therapeutic area. Both the parties will co-exclusively commercialize the product. The products, once commercialized, will be manufactured at partner's facility and will be marketed by both the parties. Aurobindo has an option to technology transfer at a future date. A cost-sharing arrangement has been agreed by both the parties with each of them contributing 50% of the cost incurred with an overall cap of $90 million for Aurobindo over the development period. Aurobindo would make an upfront payment of $25 million, on the effective date of the agreement. Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The pharma major reported 7.95% rise in consolidated net profit to Rs 817.38 crore on a 6.93% increase in revenue from operations to Rs 7,646.21 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live